British PM braces for “partygate” report as England scraps indoor mask requirements and vaccine passports; Moderna follows Pfizer in launching trial to target Omicron
Moderna Inc says it has started a mid-stage study, testing a booster dose of its Covid-19 vaccine specifically designed to target the Omicron variant, a day after rival Pfizer Inc launched a similar trial. The pharmaceutical company said while a third shot of its original coronavirus vaccine increased neutralising antibodies against the variant at the lower dose, their levels declined six months after the booster dose was administered.
Vi har opsummeret denne nyhed, så du kan læse den hurtigt. Hvis du er interesseret i nyheden, kan du læse hele teksten her. Læs mere: